Summary
A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70–120 mg/m2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting. GR38032F, a 5HT3 receptor antagonist, was given 30 min prior to cisplatin as an 8-mg loading dose by i.v. infusion over 15 min, followed by continuous infusion at a rate of 1 mg/h for 24 h. Efficacy was assessed by measurement of the number of episodes of retching and vomiting occurring in the 24 h after cisplatin administration and by an assessment of nausea during the same period. In all, 26 patients were evaluable for efficacy: overall, complete control was achieved in 12 patients (46%), major control (1–2 emetic episodes), in 6 (23%); minor control (3–5 episodes), in 1 (4%); control could not be achieved (failure; >5 episodes) in 7 patients (27%). GR38032F was well tolerated, with no significant drug-related adverse events. These encouraging results should be confirmed in compariative trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bui NB, Marit G, Hoerni B (1982) High-dose metoclopramide in cancer chemotherapy-induced nausea and vomiting. Cancer Treat Rep 66:2107
Brittain RT, Butler A, Coates LH, Fortune DH, Hogan R, Hill JM, Humber DC, Humphrey PPA, Hunter DC, Ireland SJ, Jack D, Jordan CC, Oxford A, Tyers MB (1987) GR38032F, a novel selective 5HT3 receptor antagonist. Br J Pharmacol 90: 87P
Costall B, Domeney AM, Gunning SJ, Naylor RJ, Tattersall FD, Tyers MB (1987) GR38032F: a potent and novel inhibitor of cisplatin-induced emesis in the ferret. Br J Pharmacol 90: 90P
D'Acquisto RW, Tyson LB, Gralla RJ (1986) The influence of chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Oncol 5: 257
Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Bordin LA, Braun TJ, Young CW (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New Engl J Med 305: 905
Gunning SJ, Hagan RM, Tyer MB (1987) Cisplatin induces biochemical and histological changes in the small intestine of the ferrt. Br J Pharmacol 90: 135P
Hellenbrecht D, Saller R (1986) Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis. Arzneim-Forsch 36: 1845
Homesley HD, Gainey JM, Jobson VW, Welander CE, Muss HB, Wells HB (1982) Metoclopramide as an antiemetic in chemotherapy. New Engl J Med 307: 250
Humphrey PPA (1984) Peripheral 5-hydroxytryptamine receptors and their classification. Neuropharmacology 23: 1503
Kilpatrick G, Jones BJ, Tyers MB (1987) Identification and distribution of 5HT3 receptors in rat brain using radioligand binding. Nature 30: 746
Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, Groshen S, Bosl GJ, Kalman LA (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Cancer 55: 527
Kris MG, Gralla RJ, Clark RA, Tyson LB (1988) Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 6: 659
Miner WD, Sanger GJ (1986) Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 479
Roila F, Tonato M, Basurto C, Bella M, Passalacqua R, Morsia D, DiCostanzo D, Donati D, Ballatori E, Tognoni G, Franzosi MG, Del Favero A (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-bling trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5: 141
Warrington PS, Allan SG, Cornbleet MA, Macpherson JS, Smyth JF, Leonard RCF (1986) Optimising emesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. Br Med J 293: 1334
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marty, M., Droz, J.P., Pouillart, P. et al. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. Cancer Chemother. Pharmacol. 23, 389–391 (1989). https://doi.org/10.1007/BF00435842
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00435842